RxDoctor Payments Data

Jacqulyn Sheppard

Family · Huntington, WVNPI 1174133243

Payments from drug & device makers

$1,598in general payments, 2019–2025

Across 80 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$646
  • Lilly USA, LLC$347
  • Tandem Diabetes Care, Inc.$117
  • Boehringer Ingelheim$108
  • Sanofi-aventis U.S. LLC$92
  • Vivus LLC$79
  • plus $209 from 7 others

What the payments were for

  • Food & beverage$1,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,598 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$7,533
Medicare patients
58
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide248$405,853
OzempicSemaglutide113$193,196
JardianceEmpagliflozin59$76,969
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$47,289
TrulicityDulaglutide24$34,216
WegovySemaglutide11$14,642
JanuviaSitagliptin Phosphate12$13,231
Tresiba Flextouch U-100Insulin Degludec16$5,966
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,039
Humalog Kwikpen U-100Insulin Lispro15$3,607
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$2,592
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic17$1,295
Topiramate60$697
Metformin Hcl53$357
Metformin Hcl ErMetformin Hcl36$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$347$440,069272 claims
Novo NordiskOzempic, Wegovy$646$207,839124 claims
Boehringer IngelheimJardiance$108$76,96959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →